Optimizing mRNA-Loaded Lipid Nanoparticles as a Potential Tool for Protein-Replacement Therapy

Rocío Gambaro,Ignacio Rivero Berti,María José Limeres,Cristián Huck-Iriart,Malin Svensson,Silvia Fraude,Leah Pretsch,Shutian Si,Ingo Lieberwirth,Stephan Gehring,Maximiliano Cacicedo,Germán Abel Islan

DOI: https://doi.org/10.3390/pharmaceutics16060771

IF: 6.525

2024-06-07

Pharmaceutics

Abstract:Lipid nanoparticles (LNPs) tailored for mRNA delivery were optimized to serve as a platform for treating metabolic diseases. Four distinct lipid mixes (LMs) were formulated by modifying various components: LM1 (ALC-0315/DSPC/Cholesterol/ALC-0159), LM2 (ALC-0315/DOPE/Cholesterol/ALC-0159), LM3 (ALC-0315/DSPC/Cholesterol/DMG-PEG2k), and LM4 (DLin-MC3-DMA/DSPC/Cholesterol/ALC-0159). LNPs exhibited stability and homogeneity with a mean size of 75 to 90 nm, confirmed by cryo-TEM and SAXS studies. High mRNA encapsulation (95–100%) was achieved. LNPs effectively delivered EGFP-encoding mRNA to HepG2 and DC2.4 cell lines. LNPs induced cytokine secretion from human peripheral blood mononuclear cells (PBMCs), revealing that LM1, LM2, and LM4 induced 1.5- to 4-fold increases in IL-8, TNF-α, and MCP-1 levels, while LM3 showed minimal changes. Reporter mRNA expression was observed in LNP-treated PBMCs. Hemotoxicity studies confirmed formulation biocompatibility with values below 2%. In vivo biodistribution in mice post intramuscular injection showed significant mRNA expression, mainly in the liver. The modification of LNP components influenced reactogenicity, inflammatory response, and mRNA expression, offering a promising platform for selecting less reactogenic carriers suitable for repetitive dosing in metabolic disease treatment.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem this paper attempts to address is improving the effectiveness of lipid nanoparticles (LNPs) as tools for protein replacement therapy by optimizing them. Specifically, the researchers developed 4 different lipid mixtures (LMs) by adjusting various components (such as ionizable cationic lipids, phosphatidylcholine, cholesterol, and PEG lipids) to prepare LNPs, aiming for the treatment of metabolic diseases. The focus of the study includes:

1. **Improving the stability and uniformity of LNPs**: Ensuring that LNPs remain consistent in size and can effectively encapsulate mRNA.
2. **Evaluating the cellular delivery efficiency of LNPs**: Testing the ability of LNPs to deliver mRNA encoding EGFP to HepG2 and DC2.4 cell lines.
3. **Analyzing the immunoreactivity of LNPs**: Assessing the activation level of the immune system by detecting cytokine secretion in human peripheral blood mononuclear cells (PBMCs) with different lipid mixtures.
4. **Evaluating the biocompatibility and safety of LNPs**: Confirming the biocompatibility of LNPs through hemolysis experiments and conducting in vivo biodistribution experiments to assess their distribution and expression effects in mice.

Overall, this study aims to find a formulation of LNPs that can effectively deliver mRNA with low immunogenicity, thereby providing a new tool for protein replacement therapy in metabolic diseases.